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Abstract: 
Objectives. The main aim of the study is to establish response, disease-
free interval, and overall survival of cats with nasal planum squamous cell 
carcinoma treated with Sr90 plesiotherapy. A secondary aim is to 
determine whether a fractionated protocol is more effective than a single-
dose protocol in terms of response, disease-free interval and overall 
survival. The third aim is to evaluate whether we can identify prognostic 
factors that can influence overall survival.  
Methods. Retrospective study including cats with a diagnosis of nasal 
planum squamous cell carcinoma treated with Sr90 plesiotherapy in a 
single institution.  
Results. Seventy-four cats are included in the study. Thirty-two were 
treated with a fractionated protocol and 42 with a single-dose treatment. 
Sr90 plesiotherapy was able to induce complete response in 74% of cats 
with nasal planum squamous cell carcinoma. The median disease-free 
interval was 780 days (95%C.I. 383–1177) with 17% of cats experiencing 
local recurrence. The OS for all cats was 1039 days (95%C.I. 55–1528). 
The disease-free interval of cats treated with the fractionated Sr90 was 
significantly longer compared to the single-dose treatment, while response 
and overall survival were not statistically different. Other prognostic factors 
that influenced the overall survival were early stage disease, absence of 
concurrent problems and complete response to the treatment. Acute and 
long-term toxicity associated with the treatment were minimal and the 
aesthetic outcome was pleasing in almost all cases.  
Conclusions and relevance. Strontium plesiotherapy is a safe and effective 
treatment of nasal planum squamous cell carcinoma in cats. 
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Abstract 20 
Objectives. The main aim of the study is to establish response, disease-free interval, 21 and overall survival of cats with nasal planum squamous cell carcinoma treated with 22 Sr90 plesiotherapy. A secondary aim is to determine whether a fractionated 23 protocol is more effective than a single-dose protocol in terms of response, disease-24 free interval and overall survival. The third aim is to evaluate whether we can 25 identify prognostic factors that can influence overall survival. 26 
Methods. Retrospective study including cats with a diagnosis of nasal planum 27 squamous cell carcinoma treated with Sr90 plesiotherapy in a single institution. 28 
Results. Seventy-four cats are included in the study. Thirty-two were treated with a 29 fractionated protocol and 42 with a single-dose treatment. Sr90 plesiotherapy was 30 able to induce complete response in 74% of cats with nasal planum squamous cell 31 carcinoma. The median disease-free interval was 780 days (95%C.I. 383–1177) with 32 17% of cats experiencing local recurrence. The OS for all cats was 1039 days 33 (95%C.I. 55–1528). The disease-free interval of cats treated with the fractionated 34 Sr90 was significantly longer compared to the single-dose treatment, while 35 response and overall survival were not statistically different. Other prognostic 36 factors that influenced the overall survival were early stage disease, absence of 37 concurrent problems and complete response to the treatment. Acute and long-term 38 toxicity associated with the treatment were minimal and the aesthetic outcome was 39 pleasing in almost all cases. 40 
Conclusions and relevance. Strontium plesiotherapy is a safe and effective 41 treatment of nasal planum squamous cell carcinoma in cats. 42 
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Introduction 43 Squamous cell carcinoma (SCC) is one of the most common malignant skin 44 tumours in cats and accounts for between 15 and 25% of cutaneous tumours in this 45 species.1,2 Solar exposure is important in its development and SCCs of this aetiology 46 are seen almost exclusively in non-pigmented areas of the head, such as nasal 47 planum, eyelids and pinnae, with white cats or coloured cats with white areas being 48 at greater risk.3,4 49 The stage of cutaneous SCC (T-stage) is defined by the depth of invasion and 50 by the size of the lesion (Table 1).5 Feline cutaneous SCCs are relatively slow to 51 metastatise and are reported to spread to the draining lymph nodes and the lungs.4 52 Strontium plesiotherapy (Sr90) is an effective treatment of early stage nasal 53 planum SCC in cats (Tis, T1 and T2), while it is considered ineffective for advanced 54 stage SCC (T3 and T4).4 At the moment there are two radiation protocols published 55 in the veterinary literature. The first consists of a total dose of 200Gy administered 56 in 5 fractions on an alternate day basis6; the second of a total dose between 97-57 195Gy administered in a single treatment.7 Both protocols are reported to induce 58 complete remission in ~85% of cats. For cases that achieve complete remission, 59 recurrence was not reported with the fractionated protocol and we would expect a 60 low recurrence rate, while local recurrence was reported in 20% of cats treated with 61 a single fraction.6,7 62 The aim of this retrospective study is to establish response, disease-free 63 interval (DFI), and overall survival (OS) of a large cohort of cats with nasal planum 64 SCC treated with Sr90. A secondary aim is to determine whether the fractionated 65 
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protocol (5-Sr) is more effective than the single-dose protocol (1-Sr) in terms of 66 response, DFI and OS. Finally, we would like to evaluate whether we can identify 67 prognostic factors that influenced the OS. 68 
Material and Methods 69 
Case Selection 70 The database of a single institution was searched for cats treated with Sr90 71 between 1992 and 2017. Cats were included in the study if there was a histological 72 diagnosis of nasal planum SCC. Information collected for each cat includes 73 signalment (breed, age, and gender), concurrent diseases, clinical stage, staging 74 investigations, protocol used (5-Sr or 1-Sr, total dose, number of treatment fields) 75 and toxicity (acute and late using the VRTOG criteria8). 76 
Procedures 77  The strontium applicator has a 0.7cm2 active area and is attached to a hand-78 held probe with a Perspex guard. All cats received Sr90 under general anaesthesia in 79 a designated ‘Radiation controlled area’. All treatments were administered by an 80 oncologist and consisted in the application of a variable number of overlapping 81 fields to cover the entire lesion with margins of at least 2mm around the tumour. 82 The total dose prescribed and the fractionation (5-Sr or 1-Sr) depended on the 83 clinical judgement of the oncologist in charge of the case or on the owner’s 84 preference.  The 5-Sr was delivered in 5 fractions on a Monday-Wednesday-Friday 85 schedule (total dose range 200–260Gy), while the 1-Sr was delivered in a single 86 treatment (total dose range 85–140Gy). The duration of exposure to deliver the 87 prescribed dose was calculated on the day of the first treatment using an internally 88 
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developed electronic spreadsheet taking into account the source decay over the 89 time.  The dose reported is the dose delivered to the surface, while the dose at 2mm 90 depth is ~30% of the surface dose. 91 
Statistical analysis 92 The outcome measures evaluated are response, DFI and OS. The response 93 assessment (complete response [CR], partial response [PR], stable disease [SD] or 94 progressive disease [PD]) is based on RECIST criteria9 and evaluated 6 to 8 weeks 95 after treatment. When the owner could not come to the hospital for a revisit, the 96 response was assessed with a digital image sent via email. DFI was defined as the 97 period from date of the first Sr90 until date of recurrence (local in the nasal planum 98 within or without the radiation field, loco-regional to the draining lymph nodes, or 99 systemic metastasis), and OS was defined as the period from date of the first Sr90 100 until death from any cause. When the exact date of an event was unknown (for 101 example a cat died in Nov 2015) we approximated the date to the first day of the 102 month. If partial or incomplete information were available from our records, we 103 contacted the referring veterinary practice for an update. Cats without follow-up 104 after the first Sr90 were excluded. 105 Chi-square or Fisher’s exact was used to compare categorical variables. T-106 Test was used to assess normal continuous variables. Survival analysis (Kaplan 107 Meier [KM] and Log-Rank) was used to compare outcomes of the two different 108 protocols (5-Sr and 1-Sr) and to evaluate other prognostic factors. The following 109 categories were used for the statistical analyses: age (divided in quartiles), gender 110 (male neutered, male entire and female neutered), concurrent diseases (present or 111 
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absent), T-stage (early stage [Tis, T1 and T2]; late stage [T3 and T4]), total dose 112 (<135 Gy or ≥135 Gy [135 Gy was the median dose]), the number of treatment fields 113 (<3 or ≥3 [3 was the median number of fields]), recurrence for cats that achieved CR 114 (occurred or did not occur) and response to the first Sr90 (CR, PR, PD). Factors with 115 a p<0.10 were included in the Cox Multivariate Regression analysis. Results of the 116 statistical tests were considered significant for a p<0.05. 117 Commercial software was used for the statistical analysis (IBM SPSS Statistic 118 for Windows, Version 21.0, Armonk, NY, US). 119 
Results 120 
Patients 121 One-hundred-and-twenty-three cats treated with Sr90 between 1992 and 122 2017 were found in our database (Figure 1). Seventy-four cats were included in the 123 study and their mean and median age was 11.5 and 11.1 years, respectively (range 124 3.1–20.1). There were 49 neutered males, 22 neutered females, and 1 entire male. 125 Sixty-six cats were domestic short hair, 5 domestic long hair, and 1 ragdoll. Sixty-126 four cats (86%) had a coloured coat with white areas or white coat, while 4 had 127 solid colour (5%) and hair colour was unknown for 6 cats. 128 
Tumour staging and concurrent problems 129  Local stage was evaluated in all cats. The SCC was staged as in situ (Tis) in 9 130 (12%), T1 in 17 (23%), T2 in 42 (57%), T3 in 4 (5%), and T4 in 2 cats (3%). There 131 was a significant difference in the distribution of stages between the two treatment 132 groups (Pearson Chi-square; p=0.018); 1-Sr had more TIS and T1 compared to 5-Sr 133 (50% vs. 16%). All cats had pre-anaesthetic blood tests. Other investigations to 134 
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evaluate local invasion, local and distant spread, or concurrent problems were 135 performed in 44 cats (59%). Local invasion was evaluated in 5 cats (computed-136 tomography [CT] of the head), local spread in 12 cats (lymph node cytology), 137 thoracic imaging was performed in 45 cats (38 thoracic radiographs, 5 thoracic CT, 138 and 2 echocardiography), and abdominal imaging in 9 cats (7 abdominal 139 radiographs and 2 abdominal ultrasound). None of the cats presented with local or 140 distant metastases. Twenty-three cats (31%) had concurrent problems including 8 141 with heart murmur and/or cardiac disease, 5 with SCC affecting either pinnae or 142 eyelids, 4 with chronic kidney disease and hyperthyroidism, 3 with chronic kidney 143 disease, 1 with hyperthyroidism, 1 with epilepsy and 1 with pancreatic carcinoma. 144 Four cats with concurrent problems were treated with 5-Sr and 19 with 1-Sr. There 145 was a significant statistical difference in the distribution of concurrent diseases 146 between the two treatments groups (Χ2; p=0.003). 147 
Treatment  148  Thirty-two cats (43%) were treated with a 5-Sr and 42 (57%) with the 1-Sr. 149 Mean and median dose for 5-Sr was 233Gy and 235Gy, respectively (range 200–150 260Gy), while mean and median for 1-Sr was 120Gy (range 85–140Gy). There was a 151 significant statistical difference between the mean total dose of the two treatment 152 groups (T-test; p<0.001). For the overall population mean and median number of 153 treatment fields was 2.7 and 3.0, respectively, and there was no statistical difference 154 between 5-Sr and 1-Sr (T-test; p=0.30).  155 
Response, recurrence rate and DFI 156 
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 After treatment with Sr90, 55 (74%) tumours achieved CR, 16 (22%) PR, and 157 3 (4%) PD. There was a significant association between the T-stage before Sr90 and 158 response (Χ2; p=0.002). CR was achieved in 89% of cats with Tis, 94% of T1, 68% of 159 T2, 50% of T3 and 0% of T4. Of cats that received 5-Sr, 23 (72%) achieved CR, 8 160 (25%) PR and 1 (3%) PD, while of cats that received 1-Sr, 32 (76%) achieved CR, 8 161 (19%) PR and 2 (5%) PD. There was no significant statistical difference in the 162 response between 5-Sr and 1-Sr (Χ2; p=0.79). 163  Of the 55 cats achieving CR, the overall DFI was 780 days (95%C.I. 383–164 1177). The DFI was significantly longer in cats that received 5-Sr (1966 days 165 [95%C.I. 413–3518]) compared to 1-Sr (248 days [95%C.I. 0–911]) (Log-Rank; 166 p=0.004; Figure 2). Recurrence occurred in the nasal planum in 17 (31%) cats and it 167 was within the radiation field in 4 cats, marginal to the field in 2 cats, and outside 168 the radiation field in 5 cats. Among cats that experienced recurrence, 6 received 5-Sr 169 and 11 1-Sr. There was no significant difference in recurrence rate between the two 170 protocols (Χ2; p=0.74). The median time of recurrence was 251 days (95%C.I. 48–171 454) and there was no significant difference in time to recurrence between 5-Sr and 172 1-Sr (Log-Rank; p=0.41). The distribution of the total dose between SCC that 173 recurred and that did not recur was not statistically different (Mann-Whitney-U-174 test; p=0.34). After recurrence, 12 cats received a second Sr90 (all 1-Sr) and then 4 175 cats went on to receive further treatment (2 nosectomies, 1 external-beam 176 radiotherapy and 1 topical imiquimod). The median survival of these 17 cats after 177 recurrence was 974 days (95%C.I. 367–1581). 178 
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Of the 16 cats achieving PR after Sr90, 6 cats received a second Sr90 179 treatment (all 1-Sr), while 2 were treated with external-beam radiotherapy. After 180 the second Sr90, 3 cats went on to receive further treatment (1 nosectomy, 1 181 external-beam radiotherapy and 1 third treatment of Sr90). The median survival of 182 these 16 cats after the first Sr90 was 435 days (95%C.I. 166–704). 183 Three cats developed progressive disease after Sr90; the survival after Sr90 184 was 63, 65, and 290 days. The cat that lived longer was treated with external-beam 185 radiotherapy as rescue treatment. 186 
Overall survival and prognostic factors 187  During the follow-up period, 47 (64%) cats died and 27 (36%) were still 188 alive at the time of data collection.  The median OS of the 74 cats included in the 189 study was 1039 days (95%C.I. 55–1528). Cats treated with 5-Sr had an OS of 1293 190 days (95%C.I. 491–2095) and cats treated with 1-Sr of 678 days (95%C.I. 338–191 1018). There was no difference in survival between the two protocols (Log-Rank; 192 p=0.07; Figure 2). 193  Among the prognostic factors evaluated with the Log-Rank, age (p=0.11), 194 gender (p=0.29), number of treatment fields (p=0.33) and recurrence for cats that 195 achieved CR (p=0.24) were not significantly impacting on the OS, while T-stage 196 (p<0.001), presence of concurrent diseases (p=0.001), total dose (p=0.01), and 197 response to the first Sr90 (p<0.001) were significant. Results are summarised in 198 Table 2 and Figure 3.  199 The multivariate analysis (Table 3) confirmed the significance of the T-stage 200 (p<0.001), the presence of concurrent diseases (p=0.003) and the response to the 201 
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first Sr90 (p<0.001), while the total dose lost its significance (p=0.10). The risk 202 associated with individual factors was high for concurrent disease (HR 3.72) and 203 response to the first Sr90 (HR for PR 4.76; HR for PD 8.66), and low for the T-stage 204 at presentation (HR for advanced stage 0.08). 205 
Toxicity and aesthetic outcome 206 The acute toxicity was described in 19 cases. The dermatitis was classified as mild 207 (VRTOG grade 1) in 15 cats, moderate (VRTOG grade 2) in 1 cat, and severe (VRTOG 208 grade 3) in 3 cats. Long-term side effects were consistent with alopecia in all cases. 209 Three cats developed epidermal hyperplasia and hyperkeratosis confirmed on 210 histopathology. The cosmetic outcome was described by the attending clinician in 211 21 cats and judged as excellent or very good in 18 cats or pleasing with a mild 212 deformation of the cartilage in 3 cats (Figure 4).  213 
Discussion 214  Signalment and hair colour of cats included in this study was similar to 215 previous literature.6,7,10,11 The SCC was at an early local stage in the majority of cats 216 (92%) and advanced in few cases (8%). Staging for systemic disease was not 217 complete in all cats, but in none of the cases we found evidence of local or distant 218 metastasis at presentation.10 Concurrent problems were present in 31% of cats and 219 this is similar to what has been reported.7 220 The main aim of this retrospective study was to establish response and 221 outcomes of cats with nasal planum SCC treated with two different protocols of 222 Sr90. We found that Sr90 is able to induce CR in 76% of cats. The DFI for cats that 223 achieved CR was 780 days and was significantly longer with 5-Sr compared to 1-Sr. 224 
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These results are similar to a previous study describing the use of a fractionated 225 protocol; after the first Sr90, CR was achieved in 73% of cats and the DFI was 652 226 days.6 A higher response rate and DFI was seen in a study describing a single-dose 227 protocol,7 in which CR was achieved in 88% of cats and the DFI was 1710 days. The 228 better response rate could be explained with the inclusion of cats with advanced 229 disease and a lower percentage of cats with SCC in situ in our study. The difference 230 in DFI was also conspicuous considering that the DFI of cats treated with 1-Sr in our 231 study was only 248 days. The main reason for such disparity lies within the different 232 definition of DFI: in our study we defined DFI as the time between the first Sr90 and 233 the occurrence of another nasal planum SCC (within or outside the radiation field), 234 while in Hammond’s study they only considered SCC recurring within the radiation 235 field as recurrence. In our opinion, the definition of DFI we adopted is more 236 representative of the progression of the disease accounting for the ‘field 237 
carcinogenesis’ and provides more relevant information about the chances of 238 another SCC occurring.  239 From previous studies, we were expecting a low recurrence rate with 5-Sr6, 240 and a high recurrence rate with 1-Sr7. The overall recurrence rate in this study was 241 31%, but we could not demonstrate a significant difference between 5-Sr and 1-Sr 242 (8.126% versus 14.134%, respectively). Interestingly, tumour recurrence did not 243 significantly influence OS and cats lived a long time after recurrence even if 244 additional treatment was not pursued. 245  The OS in this study was 1039 days and there was no significant difference 246 between patients receiving 5-Sr and 1-Sr. Cats treated with 5-Sr had an OS of 1293 247 
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days, which was slightly longer compared to the 780 days in the Goodfellow’s 248 study6, while cats treated with 1-Sr had an OS of 678 days. Unfortunately, the 249 Hammond’s study could not be used as comparison because the authors reported 250 the tumour-specific survival (all cats that died for a cause unrelated to the SCC were 251 censored) and not the OS. 252 A secondary aim was to evaluate whether 5-Sr was more effective than 1-Sr. 253 In this study population, the only significant difference between the two treatments 254 groups was the DFI, while response rate and OS were not different. These findings 255 suggest that cats achieving CR after Sr90 enjoyed a longer DFI if they were treated 256 with 5-Sr compared to 1-Sr. However, the OS of cats treated with 5-Sr or 1-Sr was 257 not different implying that the time to recurrence is not impacting on the overall 258 survival time. From this retrospective study is not possible to establish which 259 protocol is superior and a controlled study should be prospectively designed to 260 address this aspect. 261 Our study found few prognostic factors that were significantly associated 262 with the OS in the univariate and multivariate analysis. The first one was T-stage at 263 presentation, which made perfect biological sense considering that the higher the T-264 stage the deeper the infiltration of the tumour, and given that one of the main 265 limitations of Sr90 is the poor penetration of the β-particles into the tissue. In the 266 multivariate analysis, cats with advanced stage had 8% increased risk to die 267 compared to cats with early stage.  268 The second factor was the presence of concurrent health conditions. It is intuitive 269 that cats with extension of the SCC to other sites or with systemic conditions are 270 
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likely to succumb earlier than cats with only the nasal planum SCC. Cats with a 271 concurrent problem were more likely to be treated with 1-Sr because the aim of the 272 treatment was palliative rather than curative-intent. During follow-up time cats with 273 concurrent disease were 3.72 times more likely to die than cats without any other 274 condition. 275 The third factor was the response to the first Sr90. Cats with CR of the tumour 276 survived longer than cats that had a PR or PD. Cats that achieved PR were 4.76 more 277 at risk of dying than cats that achieved CR; the risk was 8.66 times higher for cats 278 that achieved PD. This prognostic factor was also described in the Hammond’s 279 study.7  280 Finally, the total dose, as a categorical variable dichotomised by the median value, 281 was significant in the univariate analysis, but lost its significance in the multivariate 282 analysis.  The only explanation we can provide for this finding is that the dose 283 prescribed was in part biased by the judgement of the attending clinician (for 284 example small and superficial tumours were prescribed a lower total dose 285 compared with large and deep tumours; cats with concurrent problems that could 286 not be anaesthetised many times received a higher dose, etc.). This hypothesis is 287 supported by the fact that the total dose administered to cats that experienced 288 recurrence was not statistically different from cats that did not.It is possible that the 289 inconsistencies in dose prescription associated with a retrospective study as well as 290 the relatively low number of cats included in each category biased these results.  291  Acute toxicity after completing Sr90 was described in 19 cats. In the majority 292 of cases the toxicity was mild (79%), but in few cases it was classified as moderate 293 
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(5%) or severe (16%). In the authors’ experience, the treatment area becomes 294 initially mildly erythematous in the periphery and then a thick scab forms over the 295 neoplastic ulcer. Over the following 4-8 weeks, the scab becomes gradually smaller 296 and then falls off. Given that most nasal planum SCCs present clinically as non-297 healing ulcers, in some case it is difficult it might be difficult to distinguish between 298 neoplastic ulceration and radiation toxicity and the only way is to evaluate the 299 lesion progression over the time related to the treatment. Long-term side effects 300 included alopecia and, in few cases, epidermal hyperplasia and/or hyperkeratosis. 301 The latter presents clinically as scaling dermatitis or as non-healing ulcer and both 302 these presentations can be misinterpreted as recurrence. Thus, a biopsy should 303 always be performed when recurrence is suspected before recommending 304 additional treatment. According to the attending clinician and with all the 305 limitations of retrospective studies, the cosmetic outcome of most patients was 306 pleasing, but occasionally a small deformation of the underlying cartilage remained.  307 
Conclusion 308 Sr90 is a safe and effective treatment of nasal planum SCC in cats. In this 309 study, 5-Sr90 was associated with a longer DFI compared with 1-Sr, but did not 310 impact response or OS. Other important prognostic factors that affected OS are T-311 stage at presentation, presence of concurrent diseases and response to the first 312 Sr90. 313   314 
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Figure 1. Flow-chart representing the inclusion process of the cases in the present study.  
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Figure 2. KM survival plots comparing DFI (A) and OS (B) of cats treated with a fractionated (continuous 
line) or a single-dose Sr90 protocol (dotted line). There was a statistical significant difference in DFI 
(p=0.004), but not in OS (p=0.07).  
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Figure 3. KM survival plots of significant prognostic factors affecting the OS. A- T stage (early stage 
continuous line; advanced stage dotted line) (p<0.001). B- Concurrent diseases (absent continuous line; 
present dotted line) (p=0.001). C- Total dose divided by the median value (≥135 Gy continuous line; <135 
Gy dotted line) (p=0.01). D- Response to the first Sr90 (CR continuous line; PR dotted line; PD dashed line) 
(p<0.001).  
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Figure 4. Three cats with nasal planum SCC before and after Sr90 plesiotherapy. A and B – Complete 
response of two small superficial SCC (Stage Tis). C and D – Complete response of an early stage SCC 
(Stage T1). E and F – Partial response of an advanced SCC (Stage T3). The nasal philtrum was treated with 
a second Sr90 treatment.  
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